Ocugen (NASDAQ:OCGN), a Malvern, Pennsylvania-based clinical-stage biotechnology company developing modifier gene therapies for ophthalmic and other diseases, on Wednesday reported financial results for the fourth quarter and full year ended December 31, 2025, alongside a business update highlighting progress across its three lead modifier gene therapy programs.
Cellectar Biosciences (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company specializing in radioconjugates, reported a significantly reduced net loss for 2025 as it transitioned its lead program, iopofosine I-131, into the final regulatory stages.
EyePoint Pharmaceuticals (NASDAQ:EYPT) entered a critical catalyst year on Wednesday, reporting full-year 2025 results and a clinical roadmap that places its lead candidate, DURAVYU, on track for its first pivotal Phase 3 readout in just months.
Stevanato Group (NYSE:STVN) reported a 19% increase in annual earnings on Wednesday, as the Italian drug containment specialist successfully leveraged a record mix of high-value products to offset persistent headwinds in its engineering segment.
HUTCHMED (NASDAQ:HCM) announced Wednesday the initiation of a Phase I/IIa clinical trial for HMPL-A580, marking the first human testing of its second antibody-targeted therapy conjugate (ATTC) for the treatment of solid tumors.
Passage Bio (NASDAQ:PASG) reported its full-year 2025 financial results on Tuesday, detailing a leaner operational structure and significant enrollment momentum for its lead gene therapy candidate in frontotemporal dementia.
Amylyx Pharmaceuticals (NASDAQ:AMLX) reported a significantly narrowed net loss for 2025 on Tuesday, as the company aggressively cut costs following its retreat from the ALS market and redirected capital toward its metabolic disease pipeline.
Prime Medicine (NASDAQ:PRME) reported full-year 2025 financial results on Tuesday, signaling a strategic shift toward commercial-stage readiness as its "search-and-replace" gene editing platform achieves its first human clinical validations.
CalciMedica (NASDAQ:CALC) reported its full-year 2025 financial results on Tuesday, outlining a path forward for its lead candidate, Auxora™, despite the recent discontinuation of its primary kidney injury study.
SOPHiA GENETICS (NASDAQ:SOPH) reported a strong finish to its fiscal year on Tuesday, pairing double-digit revenue growth with significant margin expansion as the healthcare-tech firm moves closer to its goal of operational profitability.
Esperion Therapeutics (NASDAQ:ESPR) moved to significantly broaden its cardiovascular portfolio on Tuesday, announcing a deal to acquire privately held Corstasis Therapeutics and its first-of-its-kind nasal spray for heart failure-related edema.
Precision BioSciences (NASDAQ:DTIL) announced Monday that it has achieved a $7.5 million clinical milestone under its licensing agreement with TG Therapeutics (NASDAQ:TGTX).
